Frontiers in therapeutic development of allopregnanolone for Alzheimer’s disease and other neurological disorders

por Irwin, Ronald W., Solinsky, Christine M., Brinton, Roberta Diaz
Publicado 2014

Allopregnanolone Preclinical Acute Pharmacokinetic and Pharmacodynamic Studies to Predict Tolerability and Efficacy for Alzheimer’s Disease

por Irwin, Ronald W., Solinsky, Christine M., Loya, Carlos M., Salituro, Francesco G., Rodgers, Kathleen E., Bauer, Gerhard, Rogawski, Michael A., Brinton, Roberta Diaz
Publicado 2015

Overall Adverse Event Profile of Vadadustat versus Darbepoetin Alfa for the Treatment of Anemia Associated with Chronic Kidney Disease in Phase 3 Trials

por Agarwal, Rajiv, Anand, Sanjeev, Eckardt, Kai-Uwe, Luo, Wenli, Parfrey, Patrick S., Sarnak, Mark J., Solinsky, Christine M., Vargo, Dennis L., Winkelmayer, Wolfgang C., Chertow, Glenn M.
Publicado 2023

Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical tria...

por Hernandez, Gerson D., Solinsky, Christine M., Mack, Wendy J., Kono, Naoko, Rodgers, Kathleen E., Wu, Chun‐Yi, Mollo, Ana R., Lopez, Claudia M., Pawluczyk, Sonia, Bauer, Gerhard, Matthews, Dawn, Shi, Yonggang, Law, Meng, Rogawski, Michael A., Schneider, Lon S., Brinton, Roberta D.
Publicado 2020

Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease

por Koury, Mark J., Agarwal, Rajiv, Chertow, Glenn M., Eckardt, Kai‐Uwe, Fishbane, Steven, Ganz, Tomas, Haase, Volker H., Hanudel, Mark R., Parfrey, Patrick S., Pergola, Pablo E., Roy‐Chaudhury, Prabir, Tumlin, James A., Anders, Robert, Farag, Youssef M. K., Luo, Wenli, Minga, Todd, Solinsky, Christine, Vargo, Dennis L., Winkelmayer, Wolfgang C.
Publicado 2022